0001127602-23-018423.txt : 20230609 0001127602-23-018423.hdr.sgml : 20230609 20230609161606 ACCESSION NUMBER: 0001127602-23-018423 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230607 FILED AS OF DATE: 20230609 DATE AS OF CHANGE: 20230609 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Strong Stewart W CENTRAL INDEX KEY: 0001420910 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-14041 FILM NUMBER: 231005489 MAIL ADDRESS: STREET 1: C/O HAEMONETICS CORPORATION STREET 2: 125 SUMMER STREET CITY: BOSTON STATE: MA ZIP: 02110 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: HAEMONETICS CORP CENTRAL INDEX KEY: 0000313143 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 042882273 STATE OF INCORPORATION: MA FISCAL YEAR END: 0401 BUSINESS ADDRESS: STREET 1: 125 SUMMER STREET CITY: BOSTON STATE: MA ZIP: 02110 BUSINESS PHONE: 7818487100 MAIL ADDRESS: STREET 1: 125 SUMMER STREET CITY: BOSTON STATE: MA ZIP: 02110 4 1 form4.xml PRIMARY DOCUMENT X0407 4 2023-06-07 0000313143 HAEMONETICS CORP HAE 0001420910 Strong Stewart W 125 SUMMER STREET BOSTON MA 02110 1 President, Global Hospital 0 Common Stock 2023-06-07 4 M 0 4483 56.57 A 21630 D Common Stock 2023-06-07 4 M 0 2410 57.60 A 24040 D Common Stock 2023-06-07 4 F 0 5053 88.00 D 18987 D Common Stock 2023-06-07 4 S 0 2538 88.04 D 16449 D Non-qualified Stock Option (Right to Buy) 56.57 2023-06-07 4 M 0 4483 0 D 2023-05-18 2028-05-18 Common Stock 4483 4483 D Non-qualified Stock Option (Right to Buy) 57.60 2023-06-07 4 M 0 2410 0 D 2023-05-16 2029-05-16 Common Stock 2410 7231 D This number includes unvested restricted stock units ("RSUs") previously reported. Represents shares withheld for tax obligations and for payment of the exercise price on exercised stock options reported in Table I. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.96 to $88.12, inclusive. The reporting person undertakes to provide to Haemonetics Corporation ("Haemonetics"), any security holder of Haemonetics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this report. Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. /s/ Thomas V. Powers, attorney-in-fact for Mr. Strong 2023-06-09